STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Clinical trials for STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7 trials appear
Sign up with your email to follow new studies for STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to starve and block cancer growth
Disease control OngoingThis early-phase trial tested a combination of two drugs (cediranib and selumetinib) in 19 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see how well the drugs worked together. Cediranib cuts off blo…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 01:03 UTC
-
Could a drug combo tame advanced melanoma?
Disease control OngoingThis study tested whether adding a drug called GM-CSF to the immunotherapy ipilimumab helps people with advanced melanoma live longer. About 245 patients with stage III or IV melanoma that could not be removed by surgery took part. The goal was to see if the combination improved …
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 01:01 UTC
-
Triple-Drug attack shows promise for Tough-to-Treat melanoma
Disease control OngoingThis study tests two different three-drug combinations in people with advanced melanoma that has spread or can't be removed by surgery. The drugs include immunotherapy (nivolumab) plus targeted therapies that block cancer growth signals. The goal is to see if these combinations w…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 00:59 UTC
-
New hope for tough melanoma: ibrutinib shows promise in early trial
Disease control OngoingThis study tested a drug called ibrutinib in 18 people with stage IV melanoma that had not responded to previous treatments. The goal was to see if the drug could shrink tumors and to study biological markers linked to response or resistance. Ibrutinib works by blocking certain e…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:53 UTC
-
Triple therapy may boost melanoma survival
Disease control OngoingThis study tests whether adding a drug called sargramostim to two immunotherapy drugs (nivolumab and ipilimumab) helps people with advanced melanoma that cannot be removed by surgery. About 600 adults with stage III or IV melanoma will take part. The goal is to see if the three-d…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:53 UTC
-
Could drug holidays work for advanced melanoma? new study investigates
Disease control OngoingThis study tests whether taking a break from two targeted cancer drugs (dabrafenib and trametinib) works as well as taking them continuously for people with advanced melanoma that has a specific BRAF mutation. About 280 participants with stage III or IV melanoma that cannot be su…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:52 UTC
-
Experimental combo targets cancer cell recycling in Late-Stage tumors
Disease control OngoingThis early-phase trial tests the safety and best dose of two drugs—MK-2206 and hydroxychloroquine—given together to people with advanced solid tumors, melanoma, prostate, or kidney cancer. The goal is to see if blocking a process called autophagy can help kill more cancer cells. …
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:49 UTC
-
Two-Drug attack on tough melanoma shows early promise
Disease control OngoingThis early-phase study tested a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ibrutinib (which blocks certain enzymes that help cancer grow)—in 20 people with advanced melanoma that could not be surgically removed. The mai…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New combo therapy shows promise in advanced skin cancer trial
Disease control OngoingThis study tested two different doses of the immunotherapy drug ipilimumab, either alone or combined with high-dose interferon, in 88 people with advanced melanoma that could not be removed by surgery. The goal was to see if the combination could delay cancer growth better than i…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Major trial tests which immune drug best stops melanoma comeback
Disease control OngoingThis study tested whether the immunotherapy drug ipilimumab works better than high-dose interferon alfa-2b at preventing melanoma from coming back after surgery. About 1,673 patients with high-risk stage III–IV melanoma that was fully removed took part. The main goal was to see w…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New combo therapy gives hope to melanoma patients who failed standard treatment
Disease control OngoingThis study tests whether combining two immunotherapy drugs—T-VEC (a virus-based therapy injected into tumors) and pembrolizumab (an antibody given by IV)—can shrink tumors in people with advanced melanoma that no longer responds to standard immunotherapy. About 43 adults with sta…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tested the safety and best dose of two drugs—riluzole and sorafenib—given together to adults with advanced solid tumors or melanoma that had spread and stopped responding to standard treatments. The goal was to find a dose that limits side effects while pot…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
Inhaled therapy shows promise for lung metastases
Disease control OngoingThis study tests an inhaled form of a protein called interleukin-2 (IL-2) to treat cancers that have spread to the lungs, such as melanoma, kidney cancer, and sarcoma. The goal is to find the safest dose and see if it can shrink tumors. About 70 adults with advanced cancer and lu…
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New drug shows promise in slowing advanced melanoma
Disease control OngoingThis study tests a drug called dinaciclib in 72 people with stage IV melanoma that has spread. The drug works by blocking enzymes that help cancer cells grow. The goal is to see if it can shrink tumors or slow the disease, and to check for side effects.
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 07, 2026 18:43 UTC
-
Supercharged immune cells take on melanoma in early trial
Disease control OngoingThis early-phase study tests a new way to fight advanced melanoma. Doctors take a patient's own immune cells (T-cells), modify them in a lab to resist a tumor-blocking signal (TGF-beta), and return them to the body along with a drug (IL-2) that boosts their activity. The goal is …
Matched conditions: STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 01, 2026 15:58 UTC